This platform technology enhances the efficacy of the drugs and reduces their toxicity. Angion Biomedica has developed a drug candidate called ANG-3777, which is a hepatocyte growth factor (HGF) mimetic. ANG-3777 has been shown to reduce inflammation ...

Ischemia Reperfusion Injury Treatment Market: Paving the Way to a $1.58 Billion Valuation by 2033 through Harmonious Healing-FMI Projection

Oxford BioMedica PLC (LON:OXB) has signed an out-licensing deal with Axovant for its Parkinson’s disease (PD) gene therapy AXO-Lenti-PD (previously OXB-102) worth up to... Oxford Biomedica plc ...

Oxford BioMedica PLC (OXB)

U.K.-based public health charity Wellcome has not shied away from its ambitious goal of donating 16 billion pounds sterling by 2032. Now, the organization has a new chief to oversee the mission.

Chutes & Ladders—CEPI's founding CEO set to lead public health charity Wellcome

Elsewhere, Oxford Biomedica disclosed a purchase linked to one of its non-executive directors. The company said Sandra Juliet Ferera Hayden bought 12,000 shares on 26 September in a single ...

Director dealings: TUI, Oxford Biomedica board members linked to buys

Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law. Angion Biomedica NewsMORE Related Stocks

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting

As of October 06, 2023, Angion Biomedica Corp had a $62.8 million market capitalization, putting it in the 30th percentile of companies in the Biotechnology & Medical Research industry. Angion Biomedica Corp does not have a meaningful P/E due to negative ...

Is Angion Biomedica Corp (ELTX) Stock a Good Investment?

Our report on the Global Ischemia Reperfusion Injury Therapeutics Market provides insights into the current market conditions, trends, competitive landscape, and emerging technologies. This market ...

Ischemia Reperfusion Injury Therapeutics Market Market Share |Scope|Forecast

The global liver diseases treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the liver diseases treatment market worldwide.

Liver Diseases Treatment Market | Abbott Laboratories, Achillion Pharmaceuticals, Angion Biomedica, BPL Medical Technologies

Disclosure: The author has stock ownership/equity in Angion Biomedica and Intercept Pharmaceuticals and is a consultant for Genzyme Pharmaceuticals, Idun Pharmaceuticals, Maxim Pharmaceuticals ...

Mechanisms of Disease: Mechanisms of Hepatic Fibrosis and Therapeutic Implications

The "Idiopathic Pulmonary Fibrosis Treatment Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. The global idiopathic pulmonary fibrosis (IPF) treatment market is expected to experience significant growth,

Leading Companies like Roche and Novartis at the Helm of the Global Rapidly Expanding IPF Treatment Market to 2030

Angion Biomedica

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York.

ANGION BIOMEDICA

angion.com

employees

Since 1998

COMPANY RANKING

ANGION BIOMEDICA

EVERGREEN INDEX #2367

Representing this company? Click here to claim and customize this page!

Read More Tech Stories Related to #Angion Biomedica

Angion Biomedica WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!

ANGION BIOMEDICA

angion.com

employees

Since 1998

COMPANY RANKING

ANGION BIOMEDICA

EVERGREEN INDEX #2367

RELATED COMPANIESRANK

Representing this company? Click here to claim and customize this page!

Read More Tech Stories Related to #Angion Biomedica

Angion Biomedica WIKI

Apply to get your Tech Company News Page live on HackerNoon.com today!